MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

71.11
+0.14
+0.20%
After Hours: 71.11 0 0.00% 16:00 11/12 EST
OPEN
70.93
PREV CLOSE
70.97
HIGH
72.38
LOW
70.50
VOLUME
569.76K
TURNOVER
--
52 WEEK HIGH
102.98
52 WEEK LOW
44.58
MARKET CAP
3.50B
P/E (TTM)
-9.1449
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BPMC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BPMC News

  • Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates
  • Zacks.6d ago
  • Benzinga's Top Upgrades, Downgrades For November 6, 2019
  • Benzinga.6d ago
  • Morgan Stanley Maintains Overweight on Blueprint Medicines, Lowers Price Target to $108
  • Benzinga.6d ago
  • Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
  • PR Newswire.6d ago

More

Industry

Biotechnology & Medical Research
+0.45%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About BPMC

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
More

Webull offers Blueprint Medicines Corp (BPMC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.